Microparticles, Vector of Genetic Information During HIV Infection

Not Applicable

Completed

• Conditions: HIV,
• Interventions: Biological: Blood samples

• Registration Number: NCT01687452
• Lead Sponsor: Assistance Publique Hopitaux De Marseille

Brief Summary

The aim of the investigators study is to demonstrate in healthy subjects and a cohort of patients infected with HIV, the presence of miRNAs in circulating peripheral blood microparticles (MPs).

Detailed Description

Not available

Study Timeline

• Study Start: 2011-03
• Study First Submitted: 2011-03-31
• Primary Completion: 2012-03
• Study Completion: 2012-03
• Study First Submitted QC: 2012-09-18
• Study First Posted: 2012-09-19
• Status Verified: 2014-08
• Last Update Submitted: 2014-08-29
• Last Update Posted: 2014-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

• Age of 40 +/-10 years
• Seronegativity for the HIV 2
• Patients of the group A: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and having never received from antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
• Patients of the group B: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and under stable antiretroviral treatment for at least 6 months, with a viral load undetectable plasmatique (< 40 copies / ml)
• patients of the group C : Matching on the age (+/-3 years) to a patient
• Be considered healthy by the Investigator after a clinical examination Seronegativity for the HIV 1 confirmed in ELISA the day of the taking

Exclusion Criteria

group A et B

• Age of < 30 years and > in 50 years
• Seropositivity for the HIV 2

group C Seropositivity for the HIV 2

• Be under medicinal treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Groupe A	Blood samples	Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load \> 1000 copies / ml
group C	Blood samples	Healthy volunteers
group B	Blood samples	Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load \> 40 copies / ml

Primary Outcome Measures

Name	Time	Method
NUMBER OF miRNAs	2 YEARS

Secondary Outcome Measures

Name	Time	Method
Demonstrate the presence of miRNAs in microparticles	2 YEARS

Trial Locations

Locations (1)

Assistance Publique Hopitaux de Marseille; 🇫🇷 Marseille, France